Labiotech.eu

tourette syndrome treatment noema pharma

News and Trends 7 Dec 2020

Swiss Startup Tackles Tourette’s Syndrome Despite Recent Failures

In spite of recent failures of clinical trials from others in the field, Swiss company Noema Pharma is gearing up to develop better treatments for the neurological condition Tourette’s syndrome. Noema Pharma will use a recent €49M Series A round to bankroll the phase I development of a candidate for Tourette’s syndrome along with the […]

December 7, 2020 - 3 minutesmins - By Jonathan Smith

In Depth 7 Dec 2020

Are We Still Friends? What Brexit Means for UK Synthetic Biology

Synthetic biology is one of the big strengths of UK science, but can the country uphold its vantage point after Brexit, without the support of the EU? (Disclaimer: At the time of writing, no deal has been made between the UK and the EU following Brexit. This intrepid writer is an Irish citizen who made […]

December 7, 2020 - 8 minutesmins - By David Kirk

News and Trends 4 Dec 2020

EU Launches Pharma Strategy, Raising Both Hopes and Questions

The public’s response has been cautious after the European Union unveiled a pharmaceutical strategy last week designed to spur domestic innovation and the production of affordable, state-of-the-art therapies. Amid a boom in biotech funding driven by the Covid-19 pandemic, the European Commission (EC) is scrambling to bring its sometimes fragmented pharma regulatory framework up to […]

December 4, 2020 - 6 minutesmins - By Victor Kotsev

In Depth 30 Nov 2020

Can Anti-Aging Research Keep Us Healthy in the Long Run?

Searching for the fountain of eternal youth has been the dream of humanity for millennia. While this is still in the realm of science fiction, anti-aging companies are hoping to tackle age-related diseases by targeting the underlying biology of aging. While we’ve been hunting for immortality for millennia, there hasn’t been much success. However, an […]

November 30, 2020 - 10 minutesmins - By Jonathan Smith

gene therapy blood disorder hemophilia b

News and Trends 27 Nov 2020

uniQure Stocks Up With First Phase III Results of Hemophilia B Gene Therapy

Gene therapies for the rare blood clotting disorder hemophilia B have taken a step closer to the market as Dutch developer uniQure became the first to release interim phase III results last week. Hemophilia is an inherited disease caused by mutations to genes encoding blood clotting proteins, resulting in uncontrollable bleeds. In severe cases of […]

November 27, 2020 - 5 minutesmins - By Victor Kotsev

News and Trends 26 Nov 2020

AstraZeneca’s Covid-19 Vaccine Proves Its Worth in Phase III

A much anticipated Covid-19 vaccine, developed by the University of Oxford and AstraZeneca, achieved 70% efficacy in phase III interim data. While less effective on paper, it could prove cheaper and easier to distribute than its most advanced competitors. Scientists and politicians heartily received the announcement of promising interim clinical trial results from the Covid-19 […]

November 26, 2020 - 4 minutesmins - By Kostas Vavitsas

Expert Advice 25 Nov 2020

How to Weather Bad Press as a Biotech Company

Biomedical companies face unique challenges when it comes to media communication. Crisis communication, in particular, can make or break a company — all the more so in a sector as sensitive as healthcare. Crises can strike a biotech company at any point — the dream partner company that had shot you to fame dumps you […]

November 25, 2020 - 7 minutesmins - By Victor Kotsev

cancer treatments immuno oncology companies

News and Trends 23 Nov 2020

SynOx Joins Wave of Biotechs Attacking Solid Tumor ‘Comfort Zone’

The newly founded SynOx has become the latest startup to attack solid tumors via their ‘comfort zone’, known as the tumor microenvironment. SynOx was spun out of the UK firm Celleron Therapeutics last week with a huge Series A round of €37M. The fledgling company is developing an antibody drug that Celleron licensed from Roche […]

November 23, 2020 - 4 minutesmins - By Jonathan Smith

Interview 23 Nov 2020

CDMOs Are the Unsung Heroes of the Gene and Cell Therapy Revolution

Cell and gene therapy is booming amid the ongoing pandemic, and this is driving up demand for synthetic DNA products, often produced and delivered by CDMOs. Karen Fallen started her career at Celltech Biologics in the UK, which was acquired in 1996 by Swiss giant Lonza, a world leader in the pharmaceutical manufacturing space. She […]

November 23, 2020 - 5 minutesmins - By Helen Albert

News and Trends 20 Nov 2020

Breakthroughs in Decentralized Testing Could Contain Covid-19

Hospital facilities in Europe are being pushed to their limits as the Covid-19 pandemic continues into winter. Coronavirus testing that doesn’t require a central lab is now arriving on the scene, and it could be the solution to effectively monitor and contain the disease. Despite the recent announcements of promising phase III data on Covid-19 […]

November 20, 2020 - 4 minutesmins - By Kostas Vavitsas

News and Trends 19 Nov 2020

mRNA Stocks Soar with Final Results of BioNTech’s Covid-19 Vaccine

The field of messenger RNA therapeutics is flying high as BioNTech and Pfizer conclude a phase III trial with their Covid-19 vaccine showing 95% effectiveness. The phase III trial recruited over 43,000 volunteers to gauge whether Covid-19 infections could be prevented by a vaccine made out of messenger RNA (mRNA). One group received two doses […]

November 19, 2020 - 6 minutesmins - By Jonathan Smith

News and Trends 16 Nov 2020

Innate Immunity in Cancer Gains Recognition with Affimed’s €1.8B Deal

Last week’s €1.75B deal between the German biotech Affimed and Swiss giant Roivant backs up an emerging trend of harnessing our innate immune system to treat cancer. According to the deal’s terms, Affimed will receive €51M upfront to license to Roivant a preclinical-stage antibody drug for several undisclosed types of cancer. Roivant will handle the […]

November 16, 2020 - 3 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Swiss Startup Tackles Tourette’s Syndrome Despite Recent Failures

Are We Still Friends? What Brexit Means for UK Synthetic Biology

EU Launches Pharma Strategy, Raising Both Hopes and Questions

Can Anti-Aging Research Keep Us Healthy in the Long Run?

uniQure Stocks Up With First Phase III Results of Hemophilia B Gene Therapy

AstraZeneca’s Covid-19 Vaccine Proves Its Worth in Phase III

How to Weather Bad Press as a Biotech Company

SynOx Joins Wave of Biotechs Attacking Solid Tumor ‘Comfort Zone’

CDMOs Are the Unsung Heroes of the Gene and Cell Therapy Revolution

Breakthroughs in Decentralized Testing Could Contain Covid-19

mRNA Stocks Soar with Final Results of BioNTech’s Covid-19 Vaccine

Innate Immunity in Cancer Gains Recognition with Affimed’s €1.8B Deal

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!